Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Rubius Therapeutics, Inc. (RUBY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/11/2021 |
8-K
| Quarterly results |
| 01/13/2020 |
8-K
| Investor presentation|
Docs:
|
"Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer CAMBRIDGE, Mass., Jan. 8, 2020 -- Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Laurence Turka, M.D., as its first chief scientific officer, effective January 21, 2020. Dr. Turka, a distinguished physician-scientist in autoimmunity and translational immunology, joins Rubius from Rheos Medicines, where he was a co-founder and served as chief scientific officer. “Larry brings to Rubius exceptional insights and an extraordinary record of scientific achievement in immune-mediated d...",
"Investor Presentation of Rubius Therapeutics, Inc." |
|
|
|